Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Scholar Rock (NASDAQ:SRRK – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

AlphaQuest LLC decreased its position in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 97.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company dedicated to developing treatments for serious diseases, has granted inducement equity awards to seven newly hired ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA.

Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...